Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

852 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Comparison of RNA-Seq Results from Paired Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Glioblastoma Tissue Samples.
Esteve-Codina A, Arpi O, Martinez-García M, Pineda E, Mallo M, Gut M, Carrato C, Rovira A, Lopez R, Tortosa A, Dabad M, Del Barco S, Heath S, Bagué S, Ribalta T, Alameda F, de la Iglesia N, Balaña C; GLIOCAT Group. Esteve-Codina A, et al. PLoS One. 2017 Jan 25;12(1):e0170632. doi: 10.1371/journal.pone.0170632. eCollection 2017. PLoS One. 2017. PMID: 28122052 Free PMC article.
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S. Balana C, et al. J Neurooncol. 2016 May;127(3):569-79. doi: 10.1007/s11060-016-2065-5. Epub 2016 Feb 3. J Neurooncol. 2016. PMID: 26847813 Clinical Trial.
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Sepúlveda-Sánchez JM, Vaz MÁ, Balañá C, Gil-Gil M, Reynés G, Gallego Ó, Martínez-García M, Vicente E, Quindós M, Luque R, Ramos A, Ruano Y, Pérez-Segura P, Benavides M, Sánchez-Gómez P, Hernández-Laín A. Sepúlveda-Sánchez JM, et al. Neuro Oncol. 2017 Oct 19;19(11):1522-1531. doi: 10.1093/neuonc/nox105. Neuro Oncol. 2017. PMID: 28575464 Free PMC article. Clinical Trial.
SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017).
Martínez-Garcia M, Álvarez-Linera J, Carrato C, Ley L, Luque R, Maldonado X, Martínez-Aguillo M, Navarro LM, Vaz-Salgado MA, Gil-Gil M. Martínez-Garcia M, et al. Clin Transl Oncol. 2018 Jan;20(1):22-28. doi: 10.1007/s12094-017-1763-6. Epub 2017 Oct 30. Clin Transl Oncol. 2018. PMID: 29086250 Free PMC article.
Pseudoprogression as an adverse event of glioblastoma therapy.
Balaña C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, Verger E, Pujol T, Martinez-García M, Oleaga L, Velarde J, Mesia C, Fuentes R, Marruecos J, Del Barco S, Villà S, Carrato C, Gallego O, Gil-Gil M, Craven-Bartle J, Alameda F; GLIOCAT Group. Balaña C, et al. Cancer Med. 2017 Dec;6(12):2858-2866. doi: 10.1002/cam4.1242. Epub 2017 Nov 3. Cancer Med. 2017. PMID: 29105360 Free PMC article.
Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients.
Balaña C, Estival A, Teruel I, Hardy-Werbin M, Sepulveda J, Pineda E, Martinez-García M, Gallego O, Luque R, Gil-Gil M, Mesia C, Del Barco S, Herrero A, Berrocal A, Perez-Segura P, De Las Penas R, Marruecos J, Fuentes R, Reynes G, Velarde JM, Cardona A, Verger E, Panciroli C, Villà S. Balaña C, et al. Clin Transl Oncol. 2018 Dec;20(12):1529-1537. doi: 10.1007/s12094-018-1883-7. Epub 2018 May 8. Clin Transl Oncol. 2018. PMID: 29737461
Prognostic value of stem cell markers in glioblastoma.
Alameda F, Velarde JM, Carrato C, Vidal N, Arumí M, Naranjo D, Martinez-Garcia M, Ribalta T, Balañá C. Alameda F, et al. Biomarkers. 2019 Nov;24(7):677-683. doi: 10.1080/1354750X.2019.1652345. Epub 2019 Sep 8. Biomarkers. 2019. PMID: 31496301
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).
Balana C, Vaz MA, Manuel Sepúlveda J, Mesia C, Del Barco S, Pineda E, Muñoz-Langa J, Estival A, de Las Peñas R, Fuster J, Gironés R, Navarro LM, Gil-Gil M, Alonso M, Herrero A, Peralta S, Olier C, Perez-Segura P, Covela M, Martinez-García M, Berrocal A, Gallego O, Luque R, Perez-Martín FJ, Esteve A, Munne N, Domenech M, Villa S, Sanz C, Carrato C. Balana C, et al. Neuro Oncol. 2020 Dec 18;22(12):1851-1861. doi: 10.1093/neuonc/noaa107. Neuro Oncol. 2020. PMID: 32328662 Free PMC article. Clinical Trial.
Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.
Carrato C, Alameda F, Esteve-Codina A, Pineda E, Arpí O, Martinez-García M, Mallo M, Gut M, Lopez-Martos R, Barco SD, Ribalta T, Capellades J, Puig J, Gallego O, Mesia C, Muñoz-Marmol AM, Archilla I, Arumí M, Blanc JM, Bellosillo B, Menendez S, Esteve A, Bagué S, Hernandez A, Craven-Bartle J, Fuentes R, Vidal N, Aldecoa I, Iglesia N, Balana C. Carrato C, et al. Clin Cancer Res. 2020 Dec 15;26(24):6600-6609. doi: 10.1158/1078-0432.CCR-20-2171. Epub 2020 Sep 30. Clin Cancer Res. 2020. PMID: 32998960
852 results